Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression in Pan02 tumors from mice that were either untreated, treated with a TGFb vaccine, with an anti-IL-6R blocking antibody or the combination of the TGFb vaccine and an anti-IL-6R blocking antibody

ABSTRACT: Gene expression in Pan02 tumors from mice that were either untreated, treated with a TGFb vaccine, with an anti-IL-6R blocking antibody or the combination of the TGFb vaccine and an anti-IL-6R blocking antibody

PROVIDER: PRJNA1096817 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression in Pan02 tumors from mice that were either untreated, treated with a TGFb vaccine, with an anti-IL-6R blocking antibody or the combination of the TGFb vaccine and an anti-IL-6R blocking antibody

Project description:To investigate changes in the tumor microenvironment at a gene expression level induced by IL-6R blockade and compare it to treatment with the TGFb vaccine in a murine model of PDAC (Pan02)

2025-01-08 | GSE263363 | GEO

Virgibacillus sp. 6R strain:6R

Project description:Virgibacillus sp. 6R strain:6R Genome sequencing and assembly

| PRJNA349088 | ENA

Paraburkholderia sp. PREW-6R isolate:PREW-6R

Project description:Paraburkholderia sp. PREW-6R isolate:PREW-6R Genome sequencing

| PRJNA1102649 | ENA

Pre-existing cross-reactive antibody responses do not significantly impact inactivated COVID-19 vaccine-induced neutralization

Project description:Recent exposure to seasonal coronaviruses (sCoVs) may stimulate cross-reactive antibody responses against SARS-CoV-2. Previous studies have shown divergent results regarding protective or damaging immunity induced by prior exposure to sCoVs. It is still unknown whether pre-existing humoral immunity may play a role in the vaccine-induced neutralization and antibody responses. In this study, we collected 36 paired sera in healthy volunteers before and after immunization with inactivated SARS-CoV-2 vaccines, and analyzed the distribution and intensity of pre-existing antibody responses at the epitope level before vaccine immunization, as well as the relationship between pre-existing sCoVs immunity and vaccine-induced neutralization.

2021-10-13 | E-MTAB-11084 | biostudies-arrayexpress

Pre-existing cross-reactive antibody responses do not significantly impact inactivated COVID-19 vaccine-induced neutralization

2021-10-29 | E-MTAB-11117 | biostudies-arrayexpress

Affinity maturation broadens influenza vaccine-induced antibody responses in humans [gex]

Project description:Influenza virus vaccination remains the best strategy for combating virus infection, but vaccine efficacy is highly variable. An ideal influenza vaccine must have two attributes: one, it should be capable of inducing broadly cross-reactive antibodies that can neutralize diverse influenza virus strains; and two, it must induce long-lived antibody responses to maintain protective immunity for extended periods. Germinal center (GC) reactions are the major sites where diversification and affinity maturation of B cells occur. Whether a persistent GC response could expand the breadth of responding B cell clones following influenza vaccination in humans remains unknown. Here, we show that influenza virus vaccine-specific GC B cells persist for over nine weeks post vaccination in two out of seven individuals. These late vaccine-specific GC B cells exhibited increased somatic hypermutation (SHM) of their B cell receptors compared to early vaccine-specific GC B cells. After re-immunization with seasonal influenza virus vaccine, individuals with a persistent GC engaged vaccine-specific plasmablasts (PBs) with higher SHM frequency. Tracking the maturation of three clonally related GC B cell lineages over time revealed that late GC B cells had receptors that recognized and neutralized heterologous influenza virus strains. Thus, SHM induced by persistent GCs can broaden the antibody response to influenza virus vaccination. This indicates that seasonal influenza virus vaccination in humans can induce broadly cross-reactive antibodies that target diverse influenza virus strains.

2024-06-13 | GSE211865 | GEO

Affinity maturation broadens influenza vaccine-induced antibody responses in humans [bcr]

2024-06-13 | GSE211869 | GEO

Proteomic Analysis of Human Serum Antibody Repertoire Response to Influenza Vaccine

Project description:Proteomic profiling of serum antibody repertoire response to FluZone trivalent influenza vaccine in four healthy human subjects. Dataset consists of collected pre-vaccination (Day 0) and post-vaccination (Days 28 and 180) serum IgG samples enriched by affinity chromatography against individual monovalent inactivated components of the 2011-2012 trivalent vaccine (H1 A/California/07/2009 X-179A, H3 A/Victoria/210/2009, and B/Brisbane/60/2008).

| MSV000080184 | MassIVE

CD3/CD28 and IL-2 stimulated mouse CD8 T cells with or without anti-CD132 blocking antibody

Project description:Mouse CD8 T cells were isolated from total splenocytes from C57BL/6 mice by MACS separation. Cells were incubated for 48 h with CD3/CD28 DynaBeads and 50 ng/ml IL-2 for 48 h with or without 100 nm anti-CD132 blocking antibody. Cells were collected and RNA was isolated.

2015-03-23 | E-MTAB-2960 | biostudies-arrayexpress

Proteomic and Antibody Profiles Reveals Antigenic Composition and Signatures of Bacterial Ghost Vaccine of Brucella abortus A19

Project description:Brucellosis is an important zoonotic disease that causes great economic losses. Vaccine immunisation is the main strategy for the prevention and control of Brucellosis. Although live attenuated vaccines play important roles in the prevention of this disease, they also have several limitations, such as residual virulence and difficulty in the differentiation of immunisation and infection. We developed and evaluated a new bacteria ghost vaccine of Brucella abortus A19 by a new double inactivation method. The results showed that the bacterial ghost vaccine of Brucella represents a more safe and efficient vaccine for Brucellosis. We further characterised the antigenic components and signatures of the vaccine candidate A19BG. Here, we utilised a mass spectrometry-based label-free relative quantitative proteomics approach to investigate the global proteomics changes in A19BGs compared to its parental A19. The proteomic analysis identified 2014 proteins, 1116 of which were differentially expressed compared with those in A19. The common immunological proteins of OMPs (Bcsp31, Omp25, Omp10, Omp19, Omp28, and Omp2a), HSPs (DnaK, GroS, and GroL), and SodC were enriched in the proteome of A19BG. By protein micro array- based antibody profiling, significant differences were observed between A19BG and A19, and a number of signature immunogenic proteins were identified. Two of these proteins, BMEII0032 and BMEI0892, were confirmed to be differential diagnostic antigens for the A19BG vaccine candidate. In conclusion, using comparative proteomics and antibody profiling, protein components and signature antigens were identified for the ghost vaccine candidate A19BG, which are valuable for further developing the vaccine and its monitoring assays.

2022-05-20 | PXD031623 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data